Clinical Trial Update: A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer [Phase 1]

View source ↗

Summary

This is a completed Phase I trial evaluating the safety, tolerability and preliminary efficacy of durvalumab (MEDI4736) in combination with tremelimumab for hea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tremelimumab (tremelimumab)
• durvalumab (MEDI4736) (durvalumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Status: COMPLETED